



Symic Bio to Present at Upcoming Conferences in London and New York

SAN FRANCISCO, Nov. 9, 2017 – Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced that Ken Horne, chief executive officer, will present at the upcoming 2017 Biotech and Money Investival Showcase, organized in partnership with Jefferies LLC, and the Trout Group EU Company Showcase in London. In addition, Ken Horne will present an overview of the company platform and clinical development programs at the Piper Jaffray 29th Annual Healthcare Conference in New York. The company also plans to attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017. Details of the presentations are as follows:

Biotech and Money Investival Showcase in partnership with Jefferies LLC

Date: Tuesday, Nov. 14, 2017
Time: 1:15 p.m. GMT
Location: The Hilton Waldorf, London

The Trout Group EU Company Showcase

Date: Tuesday, Nov. 14, 2017
Time: 4 p.m. GMT
Location: Davis Polk & Wardwell LLP, London

Piper Jaffray 29th Annual Healthcare Conference

Date: Wednesday, Nov. 29, 2017
Time: 1:10 p.m. EST
Location: Lotte New York Palace, New York

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These biotherapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa

The Trout Group

(646) 378-2949

gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com